Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $163.20 | Total: $816.00 |
| 1 | 10 | $138.24 | Total: $1,382.40 |
| 1 | 25 | $117.12 | Total: $2,928.00 |
| 1 | 50 | $99.84 | Total: $4,992.00 |
| 1 | 100 | $86.40 | Total: $8,640.00 |
Overview
YX-2-107 is a selective and potent CDK6-degrading PROTAC with an IC50 value of 4.4 nM.YX-2-107 inhibits RB phosphorylation and FOXM1 expression in vitro, and inhibits the development of Ph+ ALL in rats.YX-2-107 can be used for the prophylaxis and treatment of Ph chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). YX-2-107 can be used for the prevention and treatment of Ph chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL).
Chemical Properties
| Molecular Formula | C45H51N11O9 |
| Molecular Weight | 889.95 |
| CAS Numbers | 2417408-46-7 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | O=C1NC(=O)C(N2C(=O)C=3C=CC=C(OCC(=O)NCCCCNCC(=O)N4CCN(C5=CN=C(C=C5)NC=6N=CC7=C(N6)N(C(=O)C(C(=O)C)=C7C)C8CCCC8)CC4)C3C2=O)CC1 |
Storage and Handling
0C Short Term, -20C Long Term
References
De Dominici M, et al. Selective inhibition of Ph-positive ALL cell growth through kinase-dependent and -independent effects by CDK6-specific PROTACs. Blood. 2020 Apr 30;135[18] 1560-1573.